Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Olschewski, H; Ghofrani, A; Enke, B; Reichenberger, F; Voswinckel, R; Kreckel, A; Ghofrani, S; Wiedemann, R; Schulz, R; Grimminger, F; Seeger, W.
Therapy of pulmonary arterial hypertension
Internist (Berl). 2005; 46(3):341-349
Doi: 10.1007/s00108-004-1350-0
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Olschewski Horst
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- New drugs for pulmonary arterial hypertension have shown efficacy in randomized controlled trials. Endothelin receptor antagonists (ERA) and prostanoids are most important for clinical practice. Bosentan represents the first approved orally active therapy for PAH. Besides its hepatotoxicity it is mostly well tolerated. The first approved prostanoid, epoprostenol, is currently first choice only for decompensated right heart failure in PAH. It has to be delivered continuously intravenously and is prone to complications, side effects and very high costs. Alternatively, subcutaneous treprostinil can be applied. It is less risky and expensive but may cause local pain at the infusion site. Inhaled iloprost combines the features of a prostanoid with pulmonary and intrapulmonary selectivity. Alternatively, iloprost is being used as continuous intravenous infusion. The phosphodiesterase-5 inhibitor sildenafil was effective in two randomized controlled trials but has not been approved for PAH therapy.
- Find related publications in this database (using NLM MeSH Indexing)
- Antihypertensive Agents - adverse effects
- Calcium Channel Blockers - administration and dosage
- Drug Administration Routes - administration and dosage
- Drug Interactions - administration and dosage
- Drug Therapy, Combination - administration and dosage
- Humans - administration and dosage
- Hypertension, Pulmonary - drug therapy
- Infusions, Intravenous - drug therapy
- Phosphodiesterase Inhibitors - administration and dosage
- Prostaglandins - administration and dosage
- Randomized Controlled Trials - administration and dosage
- Receptors, Endothelin - antagonists and inhibitors
- Treatment Outcome - antagonists and inhibitors
- Find related publications in this database (Keywords)
- pulmonary arterial hypertension
- pulmonary hypertension
- prostanoid
- endothelin receptor antagonist
- phosphodiesterase-5 inhibitor